©Inserm/Cantagrel, Alain, 1993
©Inserm/Cantagrel, Alain, 1993
Teams of rheumatology, respiratory medicine, genetics and the university hospital department FIRE Hospital Bichat Claude Bernard AP-HP, in collaboration with INSERM, Université Paris Diderot, the Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, have discovered that a rare allele of rs35705950 variant gene MUC5B multiply by six the risk of occurrence of pulmonary fibrosis in patients with rheumatoid arthritis (RA). This broad study of genetic association demonstrates the existence of a common genetic basis between pulmonary fibrosis associated with rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF). These results, obtained with the participation of national and international network of pulmonologists and rheumatologists, are published in the journal The New England Journal of Medicine October 20, 2018. They are a first step in understanding the diffuse interstitial lung disease (PID) of rheumatoid arthritis, a serious complication whose therapeutic management is not currently codified.
The teams tested the influence of the major genetic risk factor for idiopathic pulmonary fibrosis (IPF): rs35705950 variant gene MUC5B .
This genetic association study case-control, coordinated by Professor Philippe Dieudé in collaboration with Prof. Bruno Crestani, compared 620 patients with rheumatoid arthritis with diffuse interstitial lung disease (PID), 614 patients with rheumatoid arthritis and without PID 5448 control individuals, from 7 different countries (France, Greece, Netherlands, Japan, China, Mexico and USA).
The results of this international collaboration show a varying contribution MUC5Brs35705950 in the determination of the PID in rheumatoid arthritis.
The presence of the risk allele multiply by 3 the risk of occurrence of interstitial lung disease diffuse (PID) and by 6 that of usual interstitial pneumonia (PIC) (the most severe form of PID). Finally, an exploratory phase exploring 12 more REIT susceptibility markers suggests the existence of a common genetic architecture between IPF and pulmonary fibrosis in rheumatoid arthritis.
This work is the first to show that there are common pathways between the two diseases – pulmonary fibrosis in rheumatoid arthritis and idiopathic pulmonary fibrosis – and provides a strong argument for promoting therapeutic intervention studies in pulmonary fibrosis associated with rheumatoid arthritis, using anti-fibrotic drugs already validated in the idiopathic pulmonary fibrosis.
To know more
The diffuse interstitial lung disease (PID) is a common extra-articular manifestation and severe rheumatoid arthritis (RA) , which affects nearly 30% of RA patients, and gradually progresses to irreversible pulmonary fibrosis in about 40 to 50 % of cases. Thus, a PID occurrence is responsible for about 7 to 10% of deaths in patients with rheumatoid arthritis and median survival varies between 2 and 5 years after the onset of Respiratory symptoms. The risk factors and pathophysiological mechanisms underlying the onset of pulmonary fibrosis in RA remain largely unknown.
Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by progressive fibrosis, in which there is no extra-respiratory disorder for which the genetic origins are known.
Pulmonary fibrosis in rheumatoid arthritis has similarities with idiopathic pulmonary fibrosis, including a high prevalence of interstitial pneumonia (PIC) , shared environmental risk factors (such as smoking) and a very poor prognosis.
A new study led by Inserm researchers from Irset, the Research Institute for Environmental and Occupational Health, shows for the first time in humans that simultaneous exposure to endocrine disruptors exacerbates the effects observed from exposure to each chemical independently. This study ...
Dr Guillaume Canaud at the Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, Inserm (INEM Institute Necker Enfants Malades – Centre for Molecular Medicine) and his team recently demonstrated the efficacy of a novel medication, a specific inhibitor called BYL719, in ...
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
NEJM – 20 octobre 2018
DOI : 10.1056/NEJMoa1801562